Vertex Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 67 to 77.
When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.
This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matched up against all other stocks.
History reveals that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves. See if Vertex Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Vertex Pharmaceuticals Stock A Buy?
Vertex Pharmaceuticals stock is building a flat base with a 325.29 entry. See if it can clear the breakout price in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings growth moved up in the company's most recent report from 14% to 25%, but revenue fell from 18% to 11%.
Vertex Pharmaceuticals stock holds the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
